Last reviewed · How we verify
NCT03550742: GRIPS
Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients
NA trial testing Fuco-N-Tetraose in Irritable Bowel Syndrome (IBS) in 317 participants. Completed in 20 March 2019.
20 March 2019
Quick facts
| Lead sponsor | Glycom, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 317 |
| Start date | 14 May 2018 |
| Primary completion | 20 March 2019 |
| Estimated completion | 20 March 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fuco-N-Tetraose
Conditions studied
- Irritable Bowel Syndrome (IBS) — all drugs for Irritable Bowel Syndrome (IBS) →
Sponsor
Glycom, Inc.
Who can join
18 and older, any sex, with Irritable Bowel Syndrome (IBS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open labeled, one-armed real-world study in IBS-patients. All participants will receive active treatment for 12 weeks. The primary objective of the study is to assess the effect of Human Milk Oligosaccharides (HMOs) on bowel function in adults with IBS. Secondary objectives are to evaluate HMOs' tolerability, effect on participant reported satisfaction with bowel habits, interference with life in general, quality of life, somatic symptoms, and anxiety and depression in all patients and subgroups of patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial.
Palsson OS, Peery A, Seitzberg D, Amundsen ID, et al · · 2020 · cited 28× · PMID 33512807 · DOI 10.14309/ctg.0000000000000276
Verify or expand the search:
- PubMed search for NCT03550742
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome (IBS)
Currently open trials in the same condition.
- NCT07481422 — Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndro · Phase 1, PHASE2 · recruiting
- NCT07261826 — Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics · recruiting
- NCT07000227 — Mechanism of FODMAP Restriction on FGID Patients · NA · recruiting
- NCT06647043 — Evaluate the Effect of Synbiotics in Irritable Bowel Syndrome · NA · recruiting
- NCT06668922 — Irritable Bowel Syndrome and Control Volunteers: Diet Challenge · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03550742 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Glycom, Inc.
- Last refreshed: 25 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03550742.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing